[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Spugnini EP, Filipponi M, Romani L, Dotsinsky I, Mudrov N, Baroni A, Ruocco E, Laieta MT, Montesarchio V, Cassandro R, Citro G, Baldi A: Local control and distant metastasis after electrochemotherapy of a canine anal melanoma. In Vivo; 2007 Sep-Oct;21(5):897-9
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local control and distant metastasis after electrochemotherapy of a canine anal melanoma.
  • Canine anal melanoma is an aggressive neoplasm that rapidly leads to constipation in dogs, thus mimicking the behavior of their human counterpart.
  • Electrochemotherapy (ECT) is a safe palliative therapy for such neoplasm and warrants further investigations in dogs as well humans.
  • [MeSH-major] Anus Neoplasms / veterinary. Dog Diseases / drug therapy. Dog Diseases / pathology. Electrochemotherapy. Melanoma / veterinary
  • [MeSH-minor] Animals. Dogs. Female. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18019432.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


2. Singer M, Mutch MG: Anal melanoma. Clin Colon Rectal Surg; 2006 May;19(2):78-87
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal melanoma.
  • Anal melanoma is rare and aggressive malignancy.
  • Unlike cutaneous melanoma, anal melanoma has no known risk factors.
  • Surgical excision remains the cornerstone of therapy.
  • There are no long-term survivors of stage II or III disease; therefore, early diagnosis and treatment remain crucial.
  • Adjuvant chemotherapy, interferon, and radiation may offer some benefit.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Apr 29;340(17):1341-8 [10219070.001]
  • [Cites] Dis Colon Rectum. 1999 Sep;42(9):1203-8 [10496563.001]
  • [Cites] Ann Surg. 1999 Oct;230(4):453-63; discussion 463-5 [10522715.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2105-16 [10561265.001]
  • [Cites] Oncology (Williston Park). 1999 Nov;13(11):1561-74; discussion 1574 passim [10581603.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):863-7 [10741708.001]
  • [Cites] Recent Results Cancer Res. 2000;157:178-89 [10857171.001]
  • [Cites] Curr Oncol Rep. 2000 Jul;2(4):292-9 [11122856.001]
  • [Cites] Chir Ital. 2000 Jul-Aug;52(4):329-34 [11190522.001]
  • [Cites] South Med J. 2001 Sep;94(9):880-5 [11592745.001]
  • [Cites] Tech Coloproctol. 2001 Apr;5(1):51-4 [11793262.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1818-25 [11919239.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):964-72 [11958890.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):438-48; discussion 448-9 [12368672.001]
  • [Cites] J Clin Oncol. 2002 Dec 1;20(23):4555-8 [12454112.001]
  • [Cites] Melanoma Res. 2002 Aug;12(4):395-8 [12170190.001]
  • [Cites] Hepatogastroenterology. 2002 Nov-Dec;49(48):1545-8 [12397731.001]
  • [Cites] Histopathology. 2002 Dec;41(6):519-25 [12460204.001]
  • [Cites] Int J Gastrointest Cancer. 2002;32(1):53-6 [12630771.001]
  • [Cites] Br J Cancer. 2003 Dec 1;89(11):2019-22 [14647131.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1478-83 [15042682.001]
  • [Cites] Radiology. 2004 Jul;232(1):181-6 [15220501.001]
  • [Cites] Anticancer Drugs. 2005 Mar;16(3):345-8 [15711188.001]
  • [Cites] J Clin Pathol. 1963 Mar;16(2):126-32 [16811001.001]
  • [Cites] Int Surg. 1980 Sep-Oct;65(5):423-6 [7451062.001]
  • [Cites] J Natl Cancer Inst. 1995 Nov 15;87(22):1710-3 [7473820.001]
  • [Cites] J Surg Oncol. 1995 Feb;58(2):118-20 [7844981.001]
  • [Cites] Dis Colon Rectum. 1995 Feb;38(2):146-51 [7851168.001]
  • [Cites] Ann N Y Acad Sci. 1993 Aug 12;690:167-77 [8368735.001]
  • [Cites] Int J Colorectal Dis. 1993 Jul;8(2):81-6 [8409692.001]
  • [Cites] Gastroenterology. 1993 Jan;104(1):174-8 [8419240.001]
  • [Cites] Histopathology. 1993 Mar;22(3):261-4 [8495957.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):88-94 [10618610.001]
  • [Cites] Ann Surg Oncol. 2000 Mar;7(2):87-97 [10761786.001]
  • [Cites] Ann Surg Oncol. 2000 Oct;7(9):680-4 [11034246.001]
  • [Cites] Surg Today. 2001;31(6):527-9 [11428607.001]
  • [Cites] Surg Oncol. 2001 Jul-Aug;10(1-2):53-9 [11719029.001]
  • [Cites] Br J Surg. 2002 Apr;89(4):389-96 [11952577.001]
  • [Cites] J Am Coll Surg. 2003 Feb;196(2):206-11 [12595048.001]
  • [Cites] Can J Surg. 2003 Oct;46(5):345-9 [14577706.001]
  • [Cites] Melanoma Res. 2004 Apr;14(2):147-50 [15057046.001]
  • [Cites] Br J Surg. 2004 Sep;91(9):1183-7 [15449271.001]
  • [Cites] Am J Surg. 2005 Apr;189(4):446-9 [15820458.001]
  • [Cites] Dis Colon Rectum. 1990 Oct;33(10):874-7 [1698595.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):729-35 [2016615.001]
  • [Cites] Surgery. 1990 Jan;107(1):1-9 [2296748.001]
  • [Cites] Arch Surg. 1990 Mar;125(3):313-6 [2306178.001]
  • [Cites] Radiother Oncol. 1989 Nov;16(3):169-82 [2587808.001]
  • [Cites] Cancer. 1988 Apr 1;61(7):1364-70 [3345491.001]
  • [Cites] Br J Surg. 1986 Jan;73(1):68-9 [3947881.001]
  • [Cites] Acta Chir Scand. 1974;140(1):68-72 [4819025.001]
  • [Cites] CA Cancer J Clin. 1966 May-Jun;16(3):111-4 [4957071.001]
  • [Cites] Dis Colon Rectum. 1967 May-Jun;10(3):161-76 [6026797.001]
  • [Cites] Cancer. 1981 Apr 1;47(7):1891-900 [6164474.001]
  • [Cites] Cancer. 1984 Mar 15;53(6):1299-305 [6362841.001]
  • [Cites] Am J Surg. 1983 Sep;146(3):336-8 [6614323.001]
  • [Cites] N Engl J Med. 1982 Oct 7;307(15):913-6 [7050717.001]
  • [Cites] Surg Gynecol Obstet. 1982 Mar;154(3):337-41 [7064068.001]
  • [Cites] Dis Colon Rectum. 1982 Oct;25(7):693-703 [7128372.001]
  • [Cites] Dis Colon Rectum. 1982 Nov-Dec;25(8):772-7 [7172945.001]
  • [Cites] Br J Surg. 1981 Sep;68(9):667-8 [7272698.001]
  • [Cites] Dis Colon Rectum. 1980 Mar;23(2):122-4 [7379659.001]
  • [Cites] Arch Surg. 1996 Sep;131(9):975-9; 979-80 [8790168.001]
  • [Cites] Ann Surg. 1996 Sep;224(3):255-63; discussion 263-6 [8813254.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):827-35 [8922197.001]
  • [Cites] Eur J Surg Oncol. 1996 Dec;22(6):598-601 [9005147.001]
  • [Cites] Surg Oncol. 1996 Aug;5(4):165-8 [9067564.001]
  • [Cites] J Exp Clin Cancer Res. 1997 Mar;16(1):81-5 [9148866.001]
  • [Cites] Dis Colon Rectum. 1997 Jun;40(6):661-8 [9194459.001]
  • [Cites] Surg Today. 1997;27(8):753-6 [9306593.001]
  • [Cites] J Am Coll Surg. 1998 Jul;187(1):69-77; discussion 77-9 [9660028.001]
  • [Cites] Eur J Surg Oncol. 1998 Aug;24(4):303-7 [9724998.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):2921-9 [9738559.001]
  • [Cites] Cancer. 1998 Oct 15;83(8):1664-78 [9781962.001]
  • [Cites] Acta Oncol. 1998;37(5):497-9 [9831382.001]
  • [Cites] Eur J Cancer. 1998 Jul;34 Suppl 3:S22-6 [9849405.001]
  • [Cites] J Natl Cancer Inst. 1998 Dec 16;90(24):1894-900 [9862627.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):476-80 [9887254.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):976-83 [10071292.001]
  • (PMID = 20011314.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780102
  • [Keywords] NOTNLM ; Melanoma / abdominoperineal resection / anal / malignancy / wide local excision
  •  go-up   go-down


3. Satzger I, Küttler U, Völker B, Schenck F, Kapp A, Gutzmer R: Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature. Dermatology; 2010;220(1):77-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
  • Previously an increased frequency of KIT aberrations in mucosal melanomas was reported, whereas c-KIT in most types of cutaneous melanomas does not appear to be of pathogenetic importance.
  • Recently 12 cases of metastatic melanoma and KIT-activating mutations have been published to be successfully treated with c-KIT blockers such as imatinib, sunitinib, dasatinib or sorafenib.
  • We report here on one of our patients with KIT-activating mutation in metastatic anal mucosal melanoma, who showed a response to imatinib therapy and summarize the available literature regarding this new therapeutic option.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Melanoma / drug therapy. Piperazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Benzamides. Female. Humans. Imatinib Mesylate. Mucous Membrane / drug effects. Mucous Membrane / pathology. Mutation. Proto-Oncogene Proteins c-kit / antagonists & inhibitors. Proto-Oncogene Proteins c-kit / genetics

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19996579.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 18
  •  go-up   go-down


Advertisement
4. Kim KB, Sanguino AM, Hodges C, Papadopoulos NE, Eton O, Camacho LH, Broemeling LD, Johnson MM, Ballo MT, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Prieto VG, Bedikian AY: Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer; 2004 Apr 1;100(7):1478-83
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biochemotherapy in patients with metastatic anorectal mucosal melanoma.
  • BACKGROUND: Patients with metastatic anorectal melanoma generally have an unfavorable prognosis, but no effective systemic therapy has been reported.
  • METHODS: The authors retrospectively evaluated the medical records of all patients with metastatic anorectal melanoma treated with biochemotherapy between January 1991 and December 2001 at the University of Texas M. D.
  • Anderson Cancer Center (Houston, TX).
  • Of these patients, 14 had undergone treatment with cisplatin (CDDP), vinblastine (VB), dacarbazine (DTIC), interferon alpha-2b (IFN), and interleukin 2 (IL-2); 2 had undergone treatment with CDDP, VB, DTIC, and IFN; 1 had undergone treatment with CDDP, IFN, and IL-2; and 1 had undergone treatment with CDDP, VB, temozolomide, IFN, and IL-2.
  • All IL-2 treatments were administered intravenously.
  • The median follow-up time was 12.2 months (range, 3.5-43.7 months).
  • Three patients were lost to follow-up evaluation after the completion of treatment.
  • The median time to progression among the 15 remaining patients was 6.2 months.
  • Among 13 patients who received biochemotherapy as first-line systemic therapy, 6 patients (46%) had major responses, including two (15%) CRs.
  • The median time to progression for this group was 6.2 months, and the median overall survival was 12.9 months.
  • CONCLUSIONS: Biochemotherapy had substantial activity against metastatic anorectal melanoma and should be considered for use in the treatment of metastatic disease from primary anorectal melanoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Melanoma / drug therapy. Melanoma / secondary
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Female. Humans. Interferon-alpha / administration & dosage. Interferon-alpha / therapeutic use. Male. Middle Aged. Recombinant Proteins. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15042682.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 5V9KLZ54CY / Vinblastine; 99210-65-8 / interferon alfa-2b; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Köksal N, Müftüoglu T, Günerhan Y, Uskent N: Complete remission of the liver metastases of anorectal malignant melanoma with regional chemotherapy: a case report. Hepatogastroenterology; 2000 May-Jun;47(33):612-4
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of the liver metastases of anorectal malignant melanoma with regional chemotherapy: a case report.
  • The prognosis of anorectal malignant melanoma is very poor.
  • We present a 48-year-old male patient with anorectal malignant melanoma and multiple liver metastases who underwent abdominoperineal resection.
  • A port system was implanted to the gastroduodenal artery for regional chemotherapy for liver metastases.
  • Both regional chemotherapy and immunotherapy were initiated 4 weeks postoperatively.
  • Computed tomography scan was taken after the 2nd and 4th cycles of chemotherapy and the tumor had not responded to chemotherapy.
  • Computed tomography and magnetic resonance imaging scans were taken on the 10th and 12th months after operation, respectively, no evidence of metastases in the liver was noted.
  • No case of complete remission of liver metastases of anorectal malignant melanoma with regional intraarterial chemotherapy and systemic immunochemotherapy has been previously reported in the literature.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Anus Neoplasms / pathology. Cisplatin / administration & dosage. Dacarbazine / administration & dosage. Infusions, Intra-Arterial. Interferon-alpha / administration & dosage. Interleukin-2 / administration & dosage. Liver Neoplasms / secondary. Melanoma / pathology. Rectal Neoplasms / pathology
  • [MeSH-minor] Humans. Immunotherapy. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10918997.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] GREECE
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Interleukin-2; 7GR28W0FJI / Dacarbazine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Yaramov N, Sokolov M, Angelov K, Petrov B, Pavlov V: [Malignant melanoma of the anus and rectum]. Khirurgiia (Sofiia); 2010;(2-3):5-7
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant melanoma of the anus and rectum].
  • There is approximately 300 cases of malignant melanoma written in the world literature.
  • We write up 13 operated from us for 15 years cases of melanoma of the anus and rectum.
  • Despite the complex treatment--surgical, chemotherapy etc. the prognosis is at large poor.
  • [MeSH-major] Anal Canal / surgery. Anus Neoplasms / surgery. Melanoma / surgery. Rectal Neoplasms / surgery. Rectum / surgery

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21972686.001).
  • [ISSN] 0450-2167
  • [Journal-full-title] Khirurgii︠a︡
  • [ISO-abbreviation] Khirurgiia (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


7. Tezuka K, Inaba Y, Hayashi K, Miura T, Moriya T, Takiguchi M, Isobe H, Watabe S, Yanagawa N: [A case of liver metastasis from anorectal malignant melanoma on hemodialysis treated by chemotherapy]. Gan To Kagaku Ryoho; 2007 Oct;34(10):1709-12
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of liver metastasis from anorectal malignant melanoma on hemodialysis treated by chemotherapy].
  • We report a case on hemodialysis with liver metastases from anorectal malignant melanoma treated by dacarbazine (DTIC).
  • A 61-year-old man presented with anal bleeding.
  • An elastic soft mass was palpated in the anal canal, and a biopsy specimen was diagnosed as anorectal malignant melanoma histologically.
  • Two and a half years after surgery, computed tomography showed multiple liver metastases.
  • We chose chemotherapy consisting of DTIC 100 mg for five consecutive days every 4 weeks in addition to hemodialysis (3 times a week).
  • After three cycles of chemotherapy, liver metastases were stable, but new lung metastases were found.
  • After 12 cycles of chemotherapy, liver metastases became stable, but lung metastases were progressive.
  • Subsequently, the patient died of respiratory failure 4 years after surgery, 1 year and 7 months after the diagnosis of multiple liver metastases.
  • We conclude that administration of DTIC undergoing hemodialysis for malignant melanoma with renal failure seems to be useful without severe adverse events.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Anus Neoplasms / pathology. Dacarbazine / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Melanoma / drug therapy. Renal Dialysis
  • [MeSH-minor] Humans. Kidney Failure, Chronic / complications. Kidney Failure, Chronic / therapy. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940397.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


8. Moozar KL, Wong CS, Couture J: Anorectal malignant melanoma: treatment with surgery or radiation therapy, or both. Can J Surg; 2003 Oct;46(5):345-9
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anorectal malignant melanoma: treatment with surgery or radiation therapy, or both.
  • INTRODUCTION: Anorectal malignant tumours are increasing in frequency for unknown reasons.
  • Surgery is the principal treatment, and the role of adjuvant therapy has not been defined.
  • We therefore decided to review the experience of the Princess Margaret Hospital in Toronto, a large tertiary care cancer hospital, with respect to the surgical management of anorectal melanoma.
  • METHODS: We reviewed the charts of all registered patients with anorectal malignant melanoma (AMM) treated with surgery or radiotherapy, or both, at the hospital between 1980 and 1999, paying particular attention to survival, and local and distant recurrences.
  • RESULTS: There were 14 patients, all of whom were followed up to the time of death or for a minimum of 28 months for surviving patients.
  • The mean ages at diagnosis were 56 years for men and 68 years for women.
  • Local therapy included local resection alone in 7 cases and abdominoperineal resection in 7.
  • Seven patients received pelvic irradiation at some time during their disease, using different doses and fractionation schemes.
  • Three of them had concomitant chemotherapy and radiotherapy with no tumour regression.
  • Six patients were alive 1 year after treatment (median survival 32.5 mo [range from 21-51 mo]).
  • The overall survival was poor regardless of local treatment.
  • [MeSH-major] Anus Neoplasms / therapy. Melanoma / therapy. Rectal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colostomy. Combined Modality Therapy. Dose Fractionation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Palliative Care. Radiotherapy Dosage. Radiotherapy, Adjuvant. Reoperation. Time Factors

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trop Gastroenterol. 2000 Apr-Jun;21(2):86-7 [10881635.001]
  • [Cites] Gastroenterology. 1993 Jan;104(1):174-8 [8419240.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):18-25 [8988722.001]
  • [Cites] Eur J Surg Oncol. 1996 Dec;22(6):598-601 [9005147.001]
  • [Cites] Surg Oncol. 1996 Aug;5(4):165-8 [9067564.001]
  • [Cites] Dis Colon Rectum. 1997 Jun;40(6):661-8 [9194459.001]
  • [Cites] Cancer. 1998 Oct 15;83(8):1664-78 [9781962.001]
  • [Cites] Acta Oncol. 1998;37(5):497-9 [9831382.001]
  • [Cites] Dis Colon Rectum. 1999 Sep;42(9):1203-8 [10496563.001]
  • [Cites] Tumori. 2000 Jul-Aug;86(4):356-8 [11016729.001]
  • [Cites] Dis Colon Rectum. 1976 May-Jun;19(4):350-6 [1084261.001]
  • [Cites] Cancer. 1981 Apr 1;47(7):1891-900 [6164474.001]
  • [Cites] Br J Surg. 1981 Sep;68(9):667-8 [7272698.001]
  • [Cites] Surg Gynecol Obstet. 1982 Mar;154(3):337-41 [7064068.001]
  • [Cites] Dis Colon Rectum. 1982 Oct;25(7):693-703 [7128372.001]
  • [Cites] Dis Colon Rectum. 1982 Nov-Dec;25(8):772-7 [7172945.001]
  • [Cites] Br J Surg. 1986 Jan;73(1):68-9 [3947881.001]
  • [Cites] Surgery. 1990 Jan;107(1):1-9 [2296748.001]
  • [Cites] Arch Surg. 1990 Mar;125(3):313-6 [2306178.001]
  • [Cites] Dis Colon Rectum. 1995 Feb;38(2):146-51 [7851168.001]
  • (PMID = 14577706.001).
  • [ISSN] 0008-428X
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC3211713
  •  go-up   go-down


9. Roviello F, Cioppa T, Marrelli D, Nastri G, De Stefano A, Hako L, Pinto E: [Primary ano-rectal melanoma: considerations on a clinical case and review of the literature]. Chir Ital; 2003 Jul-Aug;55(4):575-80
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary ano-rectal melanoma: considerations on a clinical case and review of the literature].
  • [Transliterated title] Il melanoma primitivo ano-rettale: considerazioni su un caso clinico e revisione della letteratura.
  • Anorectal melanoma is a rare disease (1% of all anorectal malignancies).
  • It is characterised by aspecific symptoms and the differential diagnosis versus other lesions of the rectum and anus is often difficult.
  • The prognosis is very poor: mean survival is about 24 months, and at diagnosis most patients present distant metastases.
  • Surgery is suggested as being the best treatment for this disease, since radio- and chemotherapy are generally only used for palliative purposes.
  • Long-term survival depends on the stage of the melanoma at diagnosis.
  • The possible surgical treatments available consist in local resection, which is considered the first therapeutic choice, and abdominoperineal amputation when local resection cannot be performed, or as a palliative operation.
  • In this report we describe a case of anorectal melanoma in a 73-year-old woman who underwent abdominoperineal amputation as surgical palliative treatment, because of infiltration of the puborectal muscle.
  • [MeSH-major] Melanoma / surgery. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12938606.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 33
  •  go-up   go-down


10. Kawano N, Tashiro M, Taguchi M, Kihara Y, Yoshikawa I, Syukuwa K, Yamasaki M, Kume K, Otsuki M: [Combined treatment with dacarbazine, nimustine, cisplatin, and tamoxifen plus interferon-beta in a patient with advanced anorectal malignant melanoma]. Nihon Shokakibyo Gakkai Zasshi; 2008 Nov;105(11):1627-33
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined treatment with dacarbazine, nimustine, cisplatin, and tamoxifen plus interferon-beta in a patient with advanced anorectal malignant melanoma].
  • A 73-year-old man, who was diagnosed as having advanced anorectal malignant melanoma (Stage IV), was treated with combination chemotherapy using dacarbazine, nimustine, cisplatin, and tamoxifen plus interferon-beta.
  • After the first course of chemotherapy, rectal tumor was decreased in size with less anal pain and liver tumor was disappeared.
  • Twenty-four months after the first treatment, the patient is survived.
  • DAC-Tam IFN-beta therapy may improve the management of patients who have advanced MM of the anorectum.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Melanoma / drug therapy. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Dacarbazine / administration & dosage. Humans. Interferon-beta / administration & dosage. Liver Neoplasms / secondary. Male. Neoplasm Staging. Nimustine / administration & dosage. Tamoxifen / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18987448.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen; 0S726V972K / Nimustine; 77238-31-4 / Interferon-beta; 7GR28W0FJI / Dacarbazine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Ishizone S, Koide N, Karasawa F, Akita N, Muranaka F, Uhara H, Miyagawa S: Surgical treatment for anorectal malignant melanoma: report of five cases and review of 79 Japanese cases. Int J Colorectal Dis; 2008 Dec;23(12):1257-62
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment for anorectal malignant melanoma: report of five cases and review of 79 Japanese cases.
  • INTRODUCTION: Anorectal malignant melanoma (AMM) is a relatively rare disease.
  • Because of its poor prognosis, the optimal surgical treatment for AMM is still controversial and difficult to determine.
  • We also review the present five cases along with 74 other Japanese cases reported between 1997 and 2006 and discuss the role of surgery in the treatment of AMM.
  • There was no significant difference in survival between AMM patients with and without adjuvant chemotherapy.
  • CONCLUSION: In conclusion, AMM patients treated by curative surgery can expect long-term survival, although the usefulness of adjuvant chemotherapy for AMM patients is controversial.
  • [MeSH-major] Anus Neoplasms / surgery. Melanoma / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Palliative Care. Rectum / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1997 Jun;40(6):661-8 [9194459.001]
  • [Cites] Ann Surg. 2006 Dec;244(6):1012-7 [17122627.001]
  • [Cites] Am J Surg. 2005 Apr;189(4):446-9 [15820458.001]
  • [Cites] Ann Plast Surg. 1992 Jan;28(1):85-8 [1642415.001]
  • [Cites] Dis Colon Rectum. 1990 Oct;33(10):874-7 [1698595.001]
  • [Cites] Melanoma Res. 2004 Apr;14(2):147-50 [15057046.001]
  • [Cites] Gastroenterology. 1993 Jan;104(1):174-8 [8419240.001]
  • [Cites] Am Surg. 2006 Oct;72(10):917-20 [17058735.001]
  • [Cites] J Clin Pathol. 1963 Mar;16(2):126-32 [16811001.001]
  • [Cites] Dis Colon Rectum. 1995 Feb;38(2):146-51 [7851168.001]
  • [Cites] Dis Colon Rectum. 2002 Oct;45(10 ):1412-5; discussion 1415-7 [12394445.001]
  • [Cites] Br J Surg. 2004 Sep;91(9):1183-7 [15449271.001]
  • [Cites] Cancer. 1981 Apr 1;47(7):1891-900 [6164474.001]
  • [Cites] Surgery. 1990 Jan;107(1):1-9 [2296748.001]
  • (PMID = 18633625.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Nakamura T, Ide H: [Malignant melanoma of the alimentary tract]. Gan To Kagaku Ryoho; 2003 May;30(5):619-25
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant melanoma of the alimentary tract].
  • We reviewed case reports of malignant melanoma in the alimentary tract and discussed the diagnosis and treatment.
  • Cases of malignant melanoma in the alimentary tract have mostly originated from the esophagus and an anorectal lesion.
  • Malignant melanoma of the alimentary tract might be more aggressive than that of the skin.
  • A combined modality treatment including progressive chemotherapy and biotherapy is expected to improve the prognosis of these patients.
  • [MeSH-major] Anus Neoplasms. Esophageal Neoplasms. Melanoma. Rectal Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Dacarbazine / administration & dosage. Diagnosis, Differential. Female. Humans. Male. Nimustine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12795092.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0S726V972K / Nimustine; 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; DAV protocol
  • [Number-of-references] 39
  •  go-up   go-down


13. Sasaki S, Kojima T, Hidemura A, Hatanaka K, Uekusa T, Ishimaru M: [A case report of anorectal malignant melanoma showing a complete response after DTIC/ACNU/VCR therapy]. Gan To Kagaku Ryoho; 2010 Oct;37(10):1999-2002
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of anorectal malignant melanoma showing a complete response after DTIC/ACNU/VCR therapy].
  • The patient was diagnosed with malignant melanoma of the anorectum using colonoscopy.
  • Cancer cells were found in regional lymph nodes.
  • Post-operative CT scan demonstrated multiple metastases in the liver, and he received two courses of combined chemotherapy, DAV regimen (dacarbazine: DTIC 100 mg iv days 1-5, nimustine hydrochloride: ACNU 100 mg iv day 1, vincristine sulfate: VCR 1 mg iv day 1), leading to a complete response.
  • However, malignant melanoma cells were found in hernia contents at the operation for left inguinal hernia, which led to a diagnosis of recurrent malignant melanoma.
  • To our knowledge, this is the first report of a complete response in a patient with multiple liver metastases of anorectal malignant melanoma after DAV regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Dacarbazine / therapeutic use. Melanoma / drug therapy. Nimustine / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Combined Modality Therapy. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Male. Middle Aged. Remission Induction. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20948273.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0S726V972K / Nimustine; 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


14. Ulmer A, Metzger S, Fierlbeck G: Successful palliation of stenosing anorectal melanoma by intratumoral injections with natural interferon-beta. Melanoma Res; 2002 Aug;12(4):395-8
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful palliation of stenosing anorectal melanoma by intratumoral injections with natural interferon-beta.
  • Anorectal malignant melanoma is an uncommon tumour.
  • Unlike for cutaneous melanoma, there are few guidelines for its optimal management.
  • In particular, very few palliative treatment strategies have been described for patients with advanced disease.
  • We report on an 80 year old patient with locally advanced anorectal melanoma nearly completely blocking the anal orifice and disseminated metastases.
  • We propose that conservative treatment strategies such as intratumoral injections with interferon-beta should be considered as a palliative treatment option for stenosing anorectal melanoma before an abdominoperineal resection is recommended.
  • [MeSH-major] Anus Neoplasms / drug therapy. Immunologic Factors / therapeutic use. Interferon-beta / therapeutic use. Melanoma / drug therapy. Palliative Care. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antineoplastic Agents, Alkylating / therapeutic use. Combined Modality Therapy. Constriction, Pathologic. Dacarbazine / therapeutic use. Female. Gastrointestinal Hemorrhage / etiology. Humans. Injections, Intralesional. Lung Neoplasms / secondary. Lymphatic Metastasis. Quality of Life. Rectal Prolapse / etiology. Remission Induction

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12170190.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Immunologic Factors; 77238-31-4 / Interferon-beta; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


15. Vietharsdóttir H, Moeller PH, Jóhannsson J, Jónasson JG: [Anal cancer in Iceland 1987-2003. A population based study]. Laeknabladid; 2006 May;92(5):365-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal cancer in Iceland 1987-2003. A population based study].
  • OBJECTIVE: Anal cancer is a rare disease.
  • The aim of this study was to describe anal cancer in Iceland in 1987-2003 with respect to incidence, histologic type, treatment, recurrence rate and survival.
  • MATERIAL AND METHODS: This is a retrospective study in which all malignant anal tumours diagnosed in Iceland in the period 1987-2003 were reviewed with respect to patient outcome.
  • This is a nationwide, population-based study of malignant tumours of the anal region.
  • RESULTS: From 1987-2003 thirty-eight patients were diagnosed with anal cancer, 28 females and 10 males.
  • The average age at diagnosis was 63.4 years.
  • Age standardized incidence rates for anal cancer in Iceland were 0.3 (+/-0.2) of 100.000 males and 0.9 (+/-0.4) of 100.000 females.
  • The remaining histologic types were malignant melanoma (n=3), adenosquamous carcinoma (n=1), adenocarcinoma (n=1), GIST (n=1) and undifferentiated carcinoma (n=2).
  • The duration of symptoms before diagnosis ranged from 2 weeks to 96 months (mean value 3.5 months).
  • Treatment modalities used were chemotherapy (n=12), radiotherapy (n=25) and local excision (n=18) and/or APR (n=5).
  • One patient received no treatment.
  • Many patients were treated with more than one treatment modality (n=18).
  • Twelve patients had recurrent cancer.
  • The mean value of the time from diagnosis of the primary to the recurrent cancer was 15.6 months (range, 5.9-117).
  • Sixteen patients remain with disease and ten have died of anal cancer.
  • The five year survival rate for patients diagnosed in the years 1987 to 1998 is 75% but cancer-specific survival is 82%.
  • CONCLUSION: Age-standardized incidence for anal cancer in Iceland is similar to other regions.
  • Average age at diagnosis, male-female ratio and prognosis is similar to reports in other studies.
  • The proportion of adenocarcinoma of the anus is lower in Iceland than elsewhere.
  • [MeSH-major] Anus Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Aged. Carcinoma / epidemiology. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Squamous Cell / epidemiology. Defecation. Female. Gastrointestinal Hemorrhage / etiology. Humans. Iceland / epidemiology. Incidence. Male. Melanoma / epidemiology. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Pain / etiology. Pruritus / epidemiology. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16741319.001).
  • [ISSN] 0023-7213
  • [Journal-full-title] Læknablađiđ
  • [ISO-abbreviation] Laeknabladid
  • [Language] ice
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Iceland
  •  go-up   go-down


16. Viale PH: Large hyperpigmented perianal tumor. Clin J Oncol Nurs; 2002 Mar-Apr;6(2):116-7, 120
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surgery is considered to be optimal therapy; however, chemotherapy and immunotherapy have been shown to be effective in a small number of patients.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / pathology. Melanoma / diagnosis. Melanoma / secondary
  • [MeSH-minor] Brain Neoplasms / secondary. Combined Modality Therapy. Diagnosis, Differential. Fatal Outcome. Female. Humans. Lung Neoplasms / secondary. Middle Aged. Palliative Care

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11889676.001).
  • [ISSN] 1092-1095
  • [Journal-full-title] Clinical journal of oncology nursing
  • [ISO-abbreviation] Clin J Oncol Nurs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Terada R, Ito S, Kobayashi M, Akama F, Tsujimura M, Ooe H: Anorectal melanoma: successful treatment by surgical excision and combination chemoimmunotherapy. Hepatogastroenterology; 2002 Nov-Dec;49(48):1545-8
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anorectal melanoma: successful treatment by surgical excision and combination chemoimmunotherapy.
  • Anorectal melanoma is an extremely rare malignancy, and has a poor prognosis mainly due to delays in diagnosis and lack of effective systemic therapy.
  • We report the case of a 63-year-old female patient with anorectal melanoma.
  • Diagnosis was established after surgery by histology and immunohistochemistry.
  • Postoperatively, the patient received combination therapy of dacarbazine, nimustine hydrochloride, vincristine sulfate, and interferon-beta for 3 cycles.
  • Ten months later, a solitary brain metastatic tumor was noted in the left occipital region, which was resected surgically followed by the above combination therapy for 2 cycles.
  • Furthermore, our case suggests that prolongation of survival may depend on extensive block resection and combination therapy of DAV and interferon-beta.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / surgery. Melanoma / drug therapy. Melanoma / surgery. Rectal Neoplasms / drug therapy. Rectal Neoplasms / surgery
  • [MeSH-minor] Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Combined Modality Therapy. Female. Humans. Immunotherapy. Interferon-beta / therapeutic use. Middle Aged

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12397731.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 77238-31-4 / Interferon-beta
  •  go-up   go-down


18. Winburn GB: Anal carcinoma or "just hemorrhoids"? Am Surg; 2001 Nov;67(11):1048-58
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma or "just hemorrhoids"?
  • Cancers of the anal margin and anal canal are extremely rare and often misdiagnosed.
  • From January 1985 through July 2000, 50 patients were diagnosed with anal cancer at two institutions.
  • This retrospective review includes all available cases of anal cancer including all histologies.
  • Patient charts were analyzed for diagnosis, staging, treatment, survival, and recurrence rate.
  • The pathologic diagnosis included 44 (88%) with squamous cell carcinoma, three (6%) with melanoma, two (4%) with adenocarcinoma, and one (2%) with Paget's disease.
  • Chemoradiotherapy was the primary treatment modality in 25 patients (50%).
  • Three patients (6%) received an APR as primary treatment, three (6%) in combination with chemoradiation, and four (8%) for salvage therapy.
  • Fourteen patients (28%) underwent wide local excision (WLE) as the primary treatment.
  • Two patients (4%) underwent WLE plus chemoradiation therapy.
  • One patient (2%) underwent WLE and chemotherapy.
  • Thirteen patients (26%) died of anal cancer; the average time to death from diagnosis was 13.2 months.
  • Three of these deaths were in patients with melanoma who presented with stage IV disease.
  • Thirty-two patients (64%) are alive, and 30 (60%) of these patients are free of disease (mean time since diagnosis 32.5 months, range 2-151 months).
  • Six patients (12%) had recurrence after treatment (mean time to recurrence 12.6 months; range 3-26 months).
  • Anal cancers continue to present at an advanced stage, with a high mortality rate.
  • Anal melanoma in particular is an aggressive and highly fatal cancer.
  • APR remains the recommended salvage therapy for advanced anal carcinomas that fail primary treatment.
  • Early recognition and detection of primary and recurrent disease is necessary for improved outcome.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Hemorrhoids / diagnosis. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11730221.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Kim TH, Chang IH, Kim TH, Lee SY, Myung SC: Extramammary Paget's disease of scrotum treated with radiotherapy. Urology; 2009 Aug;74(2):474.e1-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most cases are found on the vulva or anus.
  • EMPD must be differentiated from benign papulosquamous disease, squamous cell carcinoma and melanoma.
  • Radiation and topical chemotherapy have also been used as alternative treatment strategies and are effective for local control.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19476986.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Rousseau DL Jr, Petrelli NJ, Kahlenberg MS: Overview of anal cancer for the surgeon. Surg Oncol Clin N Am; 2004 Apr;13(2):249-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overview of anal cancer for the surgeon.
  • Cancers of the anal canal represent a diverse group of pathology and require a multidisciplinary approach for treatment.
  • For the most common anal canal cancer, anal SCC, the primary therapy is CMT with systemic chemotherapy and radiation.
  • The surgeon plays a key role in the diagnosis and follow-up after treatment, with surgical intervention reserved for residual or recurrent disease.
  • For anal adenocarcinoma, aggressive surgical resection remains the mainstay of therapy, with radiation therapy and chemotherapy used to aid in local disease control and for treatment of metastatic disease.
  • Anorectal melanoma has a high rate of distant failure and a poor overall survival rate.
  • The biggest improvements in survival for this disease will come with more effective systemic therapy.
  • [MeSH-major] Anus Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Follow-Up Studies. Humans. Melanoma / secondary. Melanoma / surgery. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery. Prognosis

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15137955.001).
  • [ISSN] 1055-3207
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 95
  •  go-up   go-down


21. Ballo MT, Gershenwald JE, Zagars GK, Lee JE, Mansfield PF, Strom EA, Bedikian AY, Kim KB, Papadopoulos NE, Prieto VG, Ross MI: Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol; 2002 Dec 1;20(23):4555-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma.
  • PURPOSE: To evaluate the outcome and toxicity of a sphincter-sparing treatment strategy in the management of patients with anal-rectal melanoma.
  • PATIENTS AND METHODS: Between 1989 and 2000, 23 patients with invasive anal-rectal melanoma were managed with sphincter-sparing surgical resection and adjuvant radiation.
  • Adjuvant radiation was delivered using a hypofractionated regimen of 30 Gy in five fractions over 2.5 weeks.
  • Adjuvant systemic therapy was delivered to nine patients: cytotoxic chemotherapy in seven and immunotherapy in two.
  • Two patients developed mild scrotal edema (grade 1), and four patients developed moderate proctitis requiring prolonged medical management (grade 2).
  • [MeSH-major] Anus Neoplasms / radiotherapy. Anus Neoplasms / surgery. Melanoma / radiotherapy. Melanoma / surgery. Rectal Neoplasms / radiotherapy. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose Fractionation. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Radiotherapy, Adjuvant. Severity of Illness Index. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12454112.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 06294
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


22. Snoj M, Rudolf Z, Cemazar M, Jancar B, Sersa G: Successful sphincter-saving treatment of anorectal malignant melanoma with electrochemotherapy, local excision and adjuvant brachytherapy. Anticancer Drugs; 2005 Mar;16(3):345-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful sphincter-saving treatment of anorectal malignant melanoma with electrochemotherapy, local excision and adjuvant brachytherapy.
  • Anorectal malignant melanoma is a rare tumor and there is no consensus on whether aggressive or local management is more appropriate.
  • Therefore, new adjuvant treatment strategies to permit local sphincter-saving excisions are warranted.
  • In our case, a large anorectal malignant melanoma was successfully treated preoperatively by electrochemotherapy with cisplatin that, by reducing the tumor size, enabled sphincter-saving local excision.
  • Fourteen months after the beginning of treatment, the patient is without signs of local recurrence and is continent.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Anus Neoplasms / drug therapy. Brachytherapy. Cisplatin / administration & dosage. Melanoma / drug therapy
  • [MeSH-minor] Drug Therapy / methods. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15711188.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Straatsma BR, Nusinowitz S, Young TA, Gordon LK, Chun MW, Rosen C, Seja E, Economou JS, Glaspy JA, Bozon V, Gomez-Navarro J, Ribas A: Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. Am J Ophthalmol; 2007 Jun;143(6):958-969
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma.
  • PURPOSE: To determine the ocular safety of CP-675,206 (Pfizer, New York, New York, USA), a fully human anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody in clinical trials of immunotherapy of metastatic melanoma.
  • DESIGN: Prospective, nonrandomized study of the eye and vision in phase I/II clinical trials of CP-675,206 in metastatic melanoma conducted at the University of California, Los Angeles.
  • METHODS: Patients with regional or distant metastatic melanoma were enrolled in phase I/II clinical trials evaluating the safety and antitumor efficacy of CP-675,206 alone or in combination with melanoma antigen peptide-pulsed dendritic cell vaccines.
  • RESULTS: Twenty patients with metastatic melanoma arising from the skin, mucosa, eye, or unknown site were evaluated.
  • A subset of patients receiving CP-675,206 demonstrated antitumor efficacy with partial response or complete response of metastatic melanoma.
  • CONCLUSIONS: In this study, CP-675,206 immunotherapy for metastatic melanoma did not adversely affect the eye or vision.
  • [MeSH-major] Antibodies, Blocking / therapeutic use. Antibodies, Monoclonal / therapeutic use. Immunoconjugates / immunology. Immunotherapy. Melanoma / therapy. Neoplasms / therapy. Ocular Physiological Phenomena. Vision, Ocular / physiology
  • [MeSH-minor] Abatacept. Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / immunology. Anus Neoplasms / pathology. Anus Neoplasms / therapy. Choroid Neoplasms / pathology. Choroid Neoplasms / therapy. Drug Therapy, Combination. Electrooculography. Electroretinography. Female. Fluorescein Angiography. Humans. MART-1 Antigen. Male. Middle Aged. Neoplasm Proteins / immunology. Prospective Studies. Skin Neoplasms / pathology. Skin Neoplasms / therapy. Treatment Outcome. Visual Acuity

  • MedlinePlus Health Information. consumer health - Cancer Immunotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17434437.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Blocking; 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Immunoconjugates; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Neoplasm Proteins; 7D0YB67S97 / Abatacept; QEN1X95CIX / tremelimumab
  •  go-up   go-down


24. Hornick JL, Jaffe ES, Fletcher CD: Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol; 2004 Sep;28(9):1133-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histiocytic sarcoma is a rare malignant neoplasm that occurs in lymph nodes, skin, and the gastrointestinal tract.
  • Seven tumors arose in soft tissue (6 lower limb; 1 upper limb), 5 in the gastrointestinal tract (1 involving both stomach and colon, 1 ileum, 2 rectum, 1 anus), 1 in the nasal cavity, and 1 in the lung.
  • Six patients were treated with postoperative radiation and 7 with chemotherapy (CHOP or ProMACE-MOPP).
  • Two tumors recurred locally, and 5 patients developed distant spread: 3 to lymph nodes, 1 to lung, and 1 to bone.
  • At the last follow-up, 2 patients have died of disseminated disease, 4 and 5 months following initial diagnosis.
  • Histiocytic sarcoma may arise primarily in soft tissue and shows reproducible histologic features, including abundant eosinophilic cytoplasm and a prominent inflammatory infiltrate.
  • Metastatic carcinoma, metastatic melanoma, and large cell non-Hodgkin lymphomas should be excluded by immunohistochemistry.

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15316312.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Dal Maso L, Polesel J, Serraino D, Lise M, Piselli P, Falcini F, Russo A, Intrieri T, Vercelli M, Zambon P, Tagliabue G, Zanetti R, Federico M, Limina RM, Mangone L, De Lisi V, Stracci F, Ferretti S, Piffer S, Budroni M, Donato A, Giacomin A, Bellù F, Fusco M, Madeddu A, Vitarelli S, Tessandori R, Tumino R, Suligoi B, Franceschi S, Cancer and AIDS Registries Linkage (CARL) Study: Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer; 2009 Mar 10;100(5):840-7
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of cancer risk in persons with AIDS in Italy in the HAART era.
  • A record-linkage study was carried out between the Italian AIDS Registry and 24 Italian cancer registries to compare cancer excess among persons with HIV/AIDS (PWHA) before and after the introduction of highly active antiretroviral therapy (HAART) in 1996.
  • SIR for Kaposi sarcoma (KS) and non-Hodgkin lymphoma greatly decreased in 1997-2004 compared with 1986-1996, but high SIRs for KS persisted in the increasingly large fraction of PWHA who had an interval of <1 year between first HIV-positive test and AIDS diagnosis.
  • A significant excess of liver cancer (SIR=6.4) emerged in 1997-2004, whereas the SIRs for cancer of the cervix (41.5), anus (44.0), lung (4.1), brain (3.2), skin (non-melanoma, 1.8), Hodgkin lymphoma (20.7), myeloma (3.9), and non-AIDS-defining cancers (2.2) were similarly elevated in the two periods.
  • The excess of some potentially preventable cancers in PWHA suggests that HAART use must be accompanied by cancer-prevention strategies, notably antismoking and cervical cancer screening programmes.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / drug therapy. Acquired Immunodeficiency Syndrome / epidemiology. Antiretroviral Therapy, Highly Active. Neoplasms / epidemiology. Neoplasms / etiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):94-100 [12838307.001]
  • [Cites] Lancet. 2009 Jan 10;373(9658):181-3 [18684500.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Apr 1;26(4):377-80 [11317082.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] J Biomed Inform. 2001 Dec;34(6):387-95 [12198758.001]
  • [Cites] Lancet Oncol. 2003 Feb;4(2):110-9 [12573353.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):84-90 [14501799.001]
  • [Cites] Antivir Ther. 2004 Feb;9(1):13-22 [15040532.001]
  • [Cites] AIDS. 2004 Jan 2;18(1):109-13 [15090836.001]
  • [Cites] J Natl Cancer Inst. 2004 Jul 21;96(14):1070-6 [15265968.001]
  • [Cites] IARC Sci Publ. 1987;(82):1-406 [3329634.001]
  • [Cites] Lancet. 1993 Feb 13;341(8842):441 [8094208.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):966-70 [9764592.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75 [15734974.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Clin Infect Dis. 2005 Jul 1;41(1):124-6; author reply 126-7 [15937776.001]
  • [Cites] AIDS Care. 2006 May;18(4):376-8 [16809116.001]
  • [Cites] Epidemiol Prev. 2006 Jan-Feb;30(1 Suppl 2):8-10, 12-28, 30-101 passim [16826725.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Arch Intern Med. 2006 Aug 14-28;166(15):1632-41 [16908797.001]
  • [Cites] Eur J Cancer Prev. 2006 Dec;15(6):554-6 [17106339.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Eur J Cancer. 2007 Apr;43(6):1085-91 [17349785.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Clin Infect Dis. 2007 Aug 15;45(4):510-3 [17638204.001]
  • [Cites] Eur J Cancer. 2007 Sep;43(14):2117-23 [17764927.001]
  • [Cites] AIDS. 2008 Jan 11;22(2):301-6 [18097233.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2007;90:1-636 [18354839.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Br J Cancer. 2008 Sep 2;99(5):800-4 [18665172.001]
  • [Cites] AIDS. 2008 Oct 18;22(16):2135-41 [18832877.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Nov 1;49(3):282-6 [18845959.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):505-7 [12888821.001]
  • (PMID = 19223894.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2653754
  • [Investigator] Zucchetto A; De Paoli A; Colamartini A; Autelitano M; Crocetti E; Marani E; Fiore AR; Tittarelli A; Rosso S; Rashid I; Donato F; Pezzarossi A; Sgargi P; La Rosa F; Franchini S; Zanier L; Cesaraccio R; Senatore G; Vercellino PC; Vittadello F; Contrino ML; Antonini S; Maspero S; La Rosa MG; Boros S; Salfa MC
  •  go-up   go-down


26. Pantanowitz L, Schlecht HP, Dezube BJ: The growing problem of non-AIDS-defining malignancies in HIV. Curr Opin Oncol; 2006 Sep;18(5):469-78
HIV InSite. treatment guidelines - Coinfection with Hepatitis Viruses and HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As HIV-infected individuals live longer due to highly active antiretroviral therapy, their risk of dying from one of these cancers is increased.
  • RECENT FINDINGS: Recent epidemiological studies have identified higher rates of carcinoma of the anus, lung, breast, skin, conjunctiva, liver and prostate; hematopoietic malignancies such as Hodgkin's lymphoma, plasma-cell neoplasia and leukemia; and other neoplasms like melanoma and leiomyosarcoma in HIV-positive patients.
  • SUMMARY: It is unclear whether the growing number of reports on non-AIDS-defining cancers reflects a true increased incidence or merely the product of increased surveillance, detection and reporting.
  • Highly active antiretroviral therapy not only promotes longevity in the HIV-positive population, but may increase their risk of developing cancer like Hodgkin's lymphoma.
  • [MeSH-major] HIV Infections / drug therapy. Neoplasms / virology
  • [MeSH-minor] Anti-Retroviral Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Causality. Comorbidity. Humans. Incidence. Risk Factors

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894295.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / P30 AI 060354
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 95
  •  go-up   go-down


27. Antonescu CR, Busam KJ, Francone TD, Wong GC, Guo T, Agaram NP, Besmer P, Jungbluth A, Gimbel M, Chen CT, Veach D, Clarkson BD, Paty PB, Weiser MR: L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer; 2007 Jul 15;121(2):257-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.
  • Activating mutations in either BRAF or NRAS are seen in a significant number of malignant melanomas, but their incidence appears to be dependent to ultraviolet light exposure.
  • More recently, activating KIT mutations have been described in rare cases of metastatic melanoma, without further reference to their clinical phenotypes.
  • In this study, we investigated a group of anal melanomas for the presence of BRAF, NRAS, KIT and PDGFRA mutations.
  • No BRAF or PDGFRA mutations were identified in either KIT positive or negative anal melanomas.
  • In vitro drug testing of stable transformant Ba/F3 KIT(L576P) mutant cells showed sensitivity for dasatinib (previously known as BMS-354825), a dual SRC/ABL kinase inhibitor, and imatinib.
  • These results suggest that a subset of anal melanomas show activating KIT mutations, which are susceptible for therapy with specific kinase inhibitors.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17372901.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA047179; United States / NCI NIH HHS / CA / P01 CA064593; United States / NCI NIH HHS / CA / P30 CA008748; United States / NIDDK NIH HHS / DK / HL/DK55748
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; RBZ1571X5H / Dasatinib
  •  go-up   go-down


28. Wilkins K, Turner R, Dolev JC, LeBoit PE, Berger TG, Maurer TA: Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol; 2006 Feb;54(2):189-206; quiz 207-10
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant melanoma and squamous cell carcinoma are examples of cutaneous malignancies that have a more aggressive course in patients with HIV.
  • The incidence of HIV-associated Kapsosi's sarcoma has markedly decreased since the advent of HIV antiretroviral therapy.
  • Other types of cutaneous lymphoma and HIV-associated pseudo-CTCL are discussed.
  • This article addresses prevention, treatment, and follow-up strategies for this at-risk population.
  • [MeSH-minor] Algorithms. Animals. Anti-Retroviral Agents / administration & dosage. Anus Neoplasms / epidemiology. Anus Neoplasms / pathology. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Herpesviridae Infections / epidemiology. Herpesvirus 8, Human / isolation & purification. Humans. Immunity, Cellular. Immunohistochemistry. Lymphoma, Large-Cell, Anaplastic / epidemiology. Lymphoma, T-Cell, Cutaneous / epidemiology. Lymphoma, T-Cell, Cutaneous / immunology. Lymphoma, T-Cell, Cutaneous / pathology. Melanoma / epidemiology. Melanoma / therapy. Papillomaviridae. Papillomavirus Infections / epidemiology. Risk Factors. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / epidemiology. Seroepidemiologic Studies

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16443048.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 274
  •  go-up   go-down


29. Yeh JJ, Weiser MR, Shia J, Hwu WJ: Response of stage IV anal mucosal melanoma to chemotherapy. Lancet Oncol; 2005 Jun;6(6):438-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response of stage IV anal mucosal melanoma to chemotherapy.
  • [MeSH-major] Anus Neoplasms / diagnosis. Melanoma / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15925823.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down






Advertisement